中外医疗
中外醫療
중외의료
China Foreign Medical Treatment
2015年
28期
147-148
,共2页
疏血通%依达拉奉%进展性脑卒中
疏血通%依達拉奉%進展性腦卒中
소혈통%의체랍봉%진전성뇌졸중
Shuxuetong%Edaravone%Progressive stroke
目的 分析疏血通联合依达拉奉治疗进展性脑卒中的临床疗效. 方法 整群选择2014年1月—2015年1月该院收治的进展性脑卒中患者98例,将患者随机分为治疗组、对照组,每组49例. 对照组给予神经营养药物、抗血小板聚集及降压、调控血糖等对症治疗;观察组在对照组基础上加用依达拉奉30 mg+氯化钠溶液100 mL静滴,2次/d; 疏血通6 mL+氯化钠溶液250 mL静滴. 疗程14 d. 结果 治疗组:基本治愈 19 例(38.78%),显著进步17例(34.69%),进步8例(16.33%),总有效率89.8%;对照组基本治愈8例(16.33%),显著进步11例(22.45%),进步9例(18.37%),总有效率57.15%,两组比较差异有统计学意义(P<0.05). 结论 疏血通联合依达拉奉治疗进展性脑卒中,临床疗效确切、安全性好,降低致残率、病死率,值得临床推广应用.
目的 分析疏血通聯閤依達拉奉治療進展性腦卒中的臨床療效. 方法 整群選擇2014年1月—2015年1月該院收治的進展性腦卒中患者98例,將患者隨機分為治療組、對照組,每組49例. 對照組給予神經營養藥物、抗血小闆聚集及降壓、調控血糖等對癥治療;觀察組在對照組基礎上加用依達拉奉30 mg+氯化鈉溶液100 mL靜滴,2次/d; 疏血通6 mL+氯化鈉溶液250 mL靜滴. 療程14 d. 結果 治療組:基本治愈 19 例(38.78%),顯著進步17例(34.69%),進步8例(16.33%),總有效率89.8%;對照組基本治愈8例(16.33%),顯著進步11例(22.45%),進步9例(18.37%),總有效率57.15%,兩組比較差異有統計學意義(P<0.05). 結論 疏血通聯閤依達拉奉治療進展性腦卒中,臨床療效確切、安全性好,降低緻殘率、病死率,值得臨床推廣應用.
목적 분석소혈통연합의체랍봉치료진전성뇌졸중적림상료효. 방법 정군선택2014년1월—2015년1월해원수치적진전성뇌졸중환자98례,장환자수궤분위치료조、대조조,매조49례. 대조조급여신경영양약물、항혈소판취집급강압、조공혈당등대증치료;관찰조재대조조기출상가용의체랍봉30 mg+록화납용액100 mL정적,2차/d; 소혈통6 mL+록화납용액250 mL정적. 료정14 d. 결과 치료조:기본치유 19 례(38.78%),현저진보17례(34.69%),진보8례(16.33%),총유효솔89.8%;대조조기본치유8례(16.33%),현저진보11례(22.45%),진보9례(18.37%),총유효솔57.15%,량조비교차이유통계학의의(P<0.05). 결론 소혈통연합의체랍봉치료진전성뇌졸중,림상료효학절、안전성호,강저치잔솔、병사솔,치득림상추엄응용.
Objective To evaluate the clinical effect of Shuxuetong injection combined with edaravone in the treatment of progres-sive stroke. Methods From January 2014 to January 2015, 98 patients with progressive stroke were randomly divided into treat-ment group and control group, 49 cases in each group. The control group was given symptomatic treatment of neural nutrition drugs, anti platelet aggregation and blood pressure, control blood sugar; observation group in the control group on the basis of the intravenous infusion of edaravone 30 mg+sodium chloride solution of 100 mL, 2 times/day;Shuxuetong 6 mL+solution of sodium chloride 250 mL intravenous drip. 14 days of treatment. Results The treatment group: cure in 19 cases (38.78%), significant progress in 17 cases (34.69%), 8 cases of progress (16.33%). The total effective rate is 89.8%; the control group cured in 8 cases (16.33%), significant progress has been made in 11 cases (22.45%), progress in 9 cases (18.37%), the total efficiency of 57.15%, the difference between the two groups is significant (P<0.05). Conclusion Stroke in progression of Shuxuetong injection combined with edaravone in treatment, clinical curative effect is exact, safe, reduce disability rate and fatality rate, worthy of clinical application.
